A New Chlamydia Vaccine on the Horizon
A first-in-human, Phase I clinical trial was successfully completed for a chlamydia vaccine, which is...
Read More...
Focus:
-
![]()
Are M&As the Key to Securing Growth in the Orphan Drugs Sector?
The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these...
Read More...
-
![]()
Pharma Technology Focus: Scottish pharma gets a health check
In this issue: the disappearing supply of pink Migraleve in the UK, drug ingredients sourced...
Read More...
-
![]()
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in...
Read More...
-
![]()
Find out about the foundation for the first drugs using microbiome bacteria in the latest issue of Pharma Technology Focus
In this issue: A new class of cancer combo treatments, antidepressants in the environment, microbiome-based...
Read More...
-
![]()
Pharma Technology Focus – Issue 77
In this issue: China’s growing pharmaceutical market, antimicrobial resistance, the rise of tech giants in...
Read More...
-
![]()
Pharma Technology Focus – Issue 76
In this issue: HPV vaccine programmes, dominantly inherited Alzheimer’s disease, a unique brain ‘fingerprint’ and...
Read More...
-
![]()
Pharma Technology Focus – Special Issue
In this issue: Manufacturing personalised medicine, the economics of CAR-T treatments, AI in drug combination...
Read More...
-
![]()
Pharma Technology Focus – Issue 74
In this issue: Boosting trust in big pharma, the highs and lows of the world’s...
Read More...
-
![]()
GSK invests $300m in 23andMe under drug development deal
GlaxoSmithKline (GSK) has formed a multi-year alliance with genetics firm 23andMe to carry out research...
Read More...
